Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) COO Sells 67,687 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $29.35, for a total transaction of $1,986,613.45. Following the completion of the transaction, the chief operating officer now directly owns 706,872 shares in the company, valued at approximately $20,746,693.20. This represents a 8.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Melissa Baird also recently made the following trade(s):

• On Tuesday, December 10th, Melissa Baird sold 85,561 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.01, for a total transaction of $2,653,246.61.
• On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $30.89 on Friday. The firm has a market capitalization of $6.75 billion, a PE ratio of 70.20 and a beta of 1.31. Hims & Hers Health, Inc. has a 1 year low of $8.51 and a 1 year high of $35.02. The firm’s 50-day moving average is $28.22 and its two-hundred day moving average is $22.18.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.04) EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Amalgamated Bank raised its holdings in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Hims & Hers Health by 140.7% during the 2nd quarter. Hsbc Holdings PLC now owns 138,224 shares of the company’s stock worth $2,727,000 after purchasing an additional 80,810 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth $303,000. Xponance Inc. purchased a new position in Hims & Hers Health in the second quarter valued at $242,000. Finally, The Manufacturers Life Insurance Company raised its stake in Hims & Hers Health by 44.9% in the second quarter. The Manufacturers Life Insurance Company now owns 116,477 shares of the company’s stock valued at $2,352,000 after buying an additional 36,081 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Morgan Stanley began coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price objective for the company. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their target price for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Piper Sandler raised their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Finally, Needham & Company LLC upped their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.